Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899259 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
NCT03899259 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 606 participants.
The verdict
NCT03899259, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
Study Summary
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899259
The ClinicalTrials.gov registry entry for NCT03899259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03899259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03899259 about?
NCT03899259 is a clinical study titled "A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata". The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
What is the current status of trial NCT03899259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2019-07-08. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT03899259?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03899259?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.